Blood-Based Biomarkers for the Prediction of Hypertrophic Cardiomyopathy Prognosis: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 17 July 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (5) , 3418-3434
Abstract
Aims: Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease. HCM is an important cause of sudden cardiac death and may also lead to outflow tract obstruction and heart failure. Disease severity is highly variable and risk stratification remains limited. Therefore, we aimed to review current knowledge of prognostic blood-based biomarkers in HCM. Methods and results: A systematic literature search was performed on PubMed, Embase, and the Cochrane library to identify studies assessing plasma or serum biomarkers for outcomes involving malignant ventricular arrhythmia, outflow tract obstruction, and heart failure. Risk of bias was assessed using the QUIPS tool. Meta-analyses were performed using the random effects method. A total of 26 unique cohort studies assessing 42 biomarkers were identified. Overall risk of bias was moderate. Thirty-two biomarkers were significantly associated to an HCM outcome in at least one study (nine biomarkers in at least two studies). In pooled analyses, cardiovascular mortality was predicted by N-terminal prohormone of brain natriuretic peptide (hazard ratio [HR] 5.38 per log[pg/mL], 95% confidence interval [CI] 2.07–14.03, P < 0.001, I2 = 0%) and high-sensitivity C-reactive protein (HR 1.30 per μg/mL, 95% CI 1.00–1.68, P = 0.05, I2 = 78%), all-cause mortality by low-density lipoprotein cholesterol (HR 0.63 per μmol/mL, 95% CI 0.49–0.80, P < 0.001, I2 = 0%), and a combined congestive heart failure, malignant ventricular arrhythmia, and stroke outcome by high-sensitivity cardiac troponin T (pooled HR 4.19 for ≥0.014 ng/mL, 95% CI 2.22–7.88, P < 0.001, I2 = 0%). Quality of evidence was low–moderate. Conclusions: Several blood-based biomarkers were identified as predictors of HCM outcomes. Additional studies are required to validate their prognostic utility within current risk stratification models.Keywords
Funding Information
- University College London Hospitals National Institute for Health Research
- Biomedical Research Centre
- Netherlands Organization for Sciences-ZonMW (VICI 91818602)
- Dutch Heart Foundation (Dekker 2015T041)
- Dutch Heart Foundation (CVON2014-40 DOSIS)
- Dutch Cardiovascular Alliance (2020B005 DOUBLE DOSE)
- Dutch Cardiovascular Alliance (CVON2015-12 eDETECT)
- ZonMw (VICI 91818602)
- Hartstichting (CVON2014‐40 DOSIS)
- Hartstichting (2020B005 DOUBLE DOSE)
- Hartstichting (CVON2015‐12 eDETECT)
- Hartstichting (Dekker 2015T041)
This publication has 35 references indexed in Scilit:
- Monocytes as a diagnostic marker of cardiovascular diseasesImmunobiology, 2012
- Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathyHeart, 2012
- 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive SummaryCirculation, 2011
- Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imagingThe International Journal of Cardiovascular Imaging, 2011
- Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic ReviewJournal of Cardiac Failure, 2009
- Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosisEuropean Heart Journal, 2008
- Natriuretic PeptidesJACC, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Uric Acid Predicts Clinical Outcomes in Heart FailureCirculation, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001